UK markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
100.56+4.81 (+5.02%)
At close: 05:39PM CEST
Full screen
Previous close95.75
Open96.33
Bid0.00 x 0
Ask0.00 x 0
Day's range96.07 - 100.62
52-week range80.95 - 106.66
Volume2,833,919
Avg. volume2,255,239
Market cap125.565B
Beta (5Y monthly)0.36
PE ratio (TTM)18.94
EPS (TTM)5.31
Earnings date28 Jul 2022
Forward dividend & yield3.33 (3.31%)
Ex-dividend date06 May 2022
1y target est111.66
  • Motley Fool

    Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

    Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.

  • Motley Fool

    Why Sanofi May Be a Frontrunner in Endemic COVID-19

    Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.

  • Globe Newswire

    Availability of the Q2 2022 Memorandum for modelling purposes

    Availability of the Q2 2022 Memorandum for modelling purposes Paris, France – June 24, 2022 - Sanofi announced today that its Q2 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q2-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non